Abbott Laboratories (ABT) Tops Q3 EPS by 1c; Narrows FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $108.33 -0.42%
EPS Growth %: +9.2%
Financial Fact:
Total Operating Cost and Expenses: 4.41B
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +9.2%
Financial Fact:
Total Operating Cost and Expenses: 4.41B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.18, $0.01 better than the analyst estimate of $1.17. Revenue for the quarter came in at $9.82 billion versus the consensus estimate of $9.65 billion.
Abbott Laboratories sees FY2011 EPS of $4.64-$4.66, versus prior guidance of $4.58-$4.68 and the consensus of $4.64.
Abbott Laboratories sees FY2011 EPS of $4.64-$4.66, versus prior guidance of $4.58-$4.68 and the consensus of $4.64.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Genesco (GCO) Tops Q2 EPS by 54c ; Offers Guidance
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
